URGN News and Press, UroGen Pharma Ltd. From 11/14/23

2023-11-14 08:18:08 ET More on UroGen Pharma UroGen Pharma's Financial And Clinical Symbiosis Seeking Alpha’s Quant Rating on UroGen Pharma Historical earnings data for UroGen Pharma Financial information for UroGen Pharma For further details s...

Continued strong growth with JELMYTO® net product revenues of $20.9 million in Q3 2023; an increase of ~30% from the same period last year Agreement with United States Food & Drug Administration (FDA) to proceed with rolling New Drug Application (NDA) for UGN-102 beginning in...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...

Results from the pivotal Phase 3 ENVISION trial studying primary chemoablation with UGN-102 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) will be presented as a late-breaking oral presentation ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

UroGen Pharma Ltd. (URGN) is expected to report $-0.89 for Q3 2023

Conference Call and Webcast Scheduled for Tuesday, November 14, 2023 at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report thir...

2023-10-09 09:11:29 ET Summary UroGen Pharma shows promising clinical data for UGN-102 and solid financials, despite operational losses. Institutional activity and stock performance signal cautious optimism, suggesting the company's disruptive potential. Investment Recommendat...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Applic...

2023-09-11 09:49:45 ET The selling stockholders of UroGen Pharma ( NASDAQ: URGN ) plans to sell 12.6 million common shares as part of a secondary offering, the company disclosed in an SEC filing on Friday after the bell. The company said it was not selling any ordina...